--- title: USJCMSP 2024 EID --- - [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/) - [Contact Us](https://www.crdfglobal.org/contact-us/) [Facebook](https://www.facebook.com/CRDFGlobal) [Instagram](https://www.instagram.com/crdfglobal/)[Linkedin](https://www.linkedin.com/company/crdf-global) [![](https://insights.crdfglobal.org/hubfs/crdf-logo.svg)](https://crdfglobal.org/) - WHO WE ARE #### [Our Story](https://crdfglobal.org/our-story/) #### [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/) #### [Leadership](https://crdfglobal.org/leadership) #### [Our Experts](https://crdfglobal.org/experts) #### [Clients & Partners](https://crdfglobal.org/partners) ![Who we are mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/06/who-we-are-menu.jpg) More than 30 years advancing international security, technology, and economic progress in over 120 countries. - WHAT WE DO #### [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/) #### [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/) #### [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/) #### [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/) #### [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/) #### [Health Security and Research](https://www.crdfglobal.org/what-we-do/global-health/) ![What we do mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/07/MegaMenu_Website_Images_Ratios_SizesWhat-We-Do-Mega-Menu.png) Addressing evolving security and prosperity challenges through strategically tailored solutions. - HOW WE DELIVER ### CORE CAPABILITIES #### [Travel & Logistics](https://crdfglobal.org/capabilities/travel-logistics/) #### [Specialized Equipment Procurement](https://crdfglobal.org/capabilities/specialized-equipment-procurement/) #### [Technical & Professional Trainings](https://crdfglobal.org/capabilities/technical-and-professional-trainings/) #### [Fellowships & Exchanges](https://crdfglobal.org/capabilities/fellowships-and-exchanges/) #### [Grants & Research Competitions](https://crdfglobal.org/capabilities/grants-research-competitions/) #### [Security Strengthening](https://crdfglobal.org/capabilities/security-strengthening/) ### INTEGRATED SOLUTIONS #### [Program Design and Management](https://crdfglobal.org/integrated-solutions/program-design-and-management/) #### [Quality Framework](https://crdfglobal.org/integrated-solutions/quality-framework/) #### [Monitoring, Evaluation and Learning](https://crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/) #### [Remote Training & Learning](https://crdfglobal.org/integrated-solutions/remote-training-and-learning/) ![How we deliver mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/01/how-we-deliver-menu-v2.jpg) Recognized leader in global program delivery, combining technical expertise with flexible, locally driven solutions. - [WHERE WE WORK](https://crdfglobal.org/where-we-work/) - [NEWS & INSIGHTS](https://www.crdfglobal.org/news/) - [CAREERS](https://crdfglobal.org/careers/) - [\> Home](https://insights.crdfglobal.org/usjcmspeid2024) - [\> General Registration](https://insights.crdfglobal.org/usjcmspeid2024-1) - [\> Speaker Registration](https://insights.crdfglobal.org/usjcmspeid2024-1-1) - [\> Plenary Agenda](https://insights.crdfglobal.org/usjcmspeid2024-agenda) - [\> Panel Agendas](https://insights.crdfglobal.org/usjcmspeid2024panels) - [\> Travel Information](https://insights.crdfglobal.org/usjcmspeid2024-travel) - [\> IDRIC Symposium](https://idric.kr/) - [\> Abstract eBooks](https://insights.crdfglobal.org/usjcmspeid2024_ebooks) --- ![USJCMSP logo5 title](https://insights.crdfglobal.org/hs-fs/hubfs/USJCMSP%20logo5%20title.jpg?width=300&height=179&name=USJCMSP%20logo5%20title.jpg "USJCMSP logo5 title") ## The Joint 24th International Conference on Emerging Infectious Diseases in the Pacific Rim of the U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) in collaboration with the 2nd International Symposium for Infectious Diseases Research Institutes Cooperation (IDRIC) ![logo1 (003)](https://insights.crdfglobal.org/hs-fs/hubfs/logo1%20(003).png?width=125&height=125&name=logo1%20(003).png "logo1 (003)") ![NIH\_Master\_Logo\_Vertical\_2Color-PNG (002)](https://insights.crdfglobal.org/hs-fs/hubfs/NIH_Master_Logo_Vertical_2Color-PNG%20(002).png?width=125&height=110&name=NIH_Master_Logo_Vertical_2Color-PNG%20(002).png "NIH_Master_Logo_Vertical_2Color-PNG (002)") ![KDCA\_KNIH\_KNIID LOGO change](https://insights.crdfglobal.org/hs-fs/hubfs/KDCA_KNIH_KNIID%20LOGO%20change.jpg?width=350&height=58&name=KDCA_KNIH_KNIID%20LOGO%20change.jpg "KDCA_KNIH_KNIID LOGO change") ![IVI\_logo (002)-1](https://insights.crdfglobal.org/hs-fs/hubfs/IVI_logo%20(002)-1.png?width=250&name=IVI_logo%20(002)-1.png "IVI_logo (002)-1") Disclaimer: The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. --- ### Immunology Panel Agenda  ###### Thursday|7 March 2024 | DAY THREE \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 8:50-9:00 | Welcome and Introduction | Conrad Mallia, U.S. National Institute of Allergy and Infectious Diseases & Ken Ishii.  9:00-9:20 | Adjuvants and Mucosal Immunity | Jun Kunisawa, National Institutes of Biomedical Innovation, Health, and Nutrition 9:20-9:30 | Discussion 9:30-9:50 | Vaccine Adjuvant Program at the University of California, San Diego | Tomoko Hayashi, UCSD 9:50-10:00 | Discussion  10:00-10:20 | Innate Immune Regulation and Lysosome-targeting Drug Development | Noriko Sorumachi, University of Tokyo, Japan 10:20-10:30 | Discussion \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 10:30-10:45 | Break \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 10:45-11:05 | Vaccine Adjuvant Development | Harry Kleanthous, SK Bioscience, Cambridge, MA / Seoul, South Korea 11:05-11:15 | Discussion 11:15-11:35 | Vaccine Adjuvant Development | Ken Ishii, Institute of Medical Science, University of Tokyo, Japan 11:35-11:45 | Discussion \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 11:45-13:30 | Lunch Break \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 13:30-13:50 | Sustainable Next Generation Saponin-based Vaccine Adjuvants | Pi-Hui Liang, ImmunAdd, Taipei City, Taiwan 13:50-14:00 | Discussion 14:00-14:20 | Vaccine Antigen and Antibody Protein Engineering | Satoru Nagatoishi, University of Tokyo, Japan 14:20-14:30 | Discussion 14:30-14:50 | Mucosal Vaccine Adjuvants and IgA | Reiko Shinkura, Laboratory of Immunology and Infection Control, University of Yokyo, Japan 14:50-15:00 | Discussion 15:00-15:20 | Non-Human Primate Models for Vaccines | Yasuhiro Yasutomi, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan 15:20-15:30 | Discussion 15:30 | Wrap-Up and Adjourn Immunology Board Session ###### Friday| 8 March 2024 | DAY FOUR \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ SESSION THREE: Hepatitis Virus-related and Non-viral Liver Cancer - Joint with Immunology Board and Cancer Panel  *Moderators: Su-Hyung Park & Toru Kiyono* 8:30-8:45 | Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication and Derived from Integrated HBV DNA | Severin Gudima, USA 8:45-9:00 | Tatsuhiro Shibata, Japan 9:00-9:15 |  Regulatory Mechanism of Polycomb Repressive Complex 1 by HCV Infection | Kohji Moriishi, Japan 9:15-9:30 | ILT2 as a Regulator of NK Cells in Patients with HCC | Tatsuya Kanto, Japan 9:30-9:45 | Moleculat Landscape of Liver Cancer and Its Clinical Implications | Xin Wei Wang, USA 9:45-10:10 | Discussion for Talks 20-24  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 10:10-10:50 | Coffee Break \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *Moderator: Tatsuya Kanto * 10:50-11:05 | 4-1BB Co-Stimulation, a Promising Strategy for Treating HCC | Su-Hyung Park, Korea 11:05-11:20 | mRNA-based T-cell Engineering for HBV-related HCC | Antonio Bertoletti, Singapore 11:20-11:35 | Ray Chung, USA 11:35-11:50 | Oxidative Stress Sensor Keap1 Recognixes HBx Protein to Activate the Nrf2/ARE Signaling Pathway, thereby Inhibiting Hepatitis B Virus Replication | Ikuo Shoji, Japan 11:50-12:05 | Epidemiology and Genomic Applications Detect Risk Factors and Discern Treatment Response in Liver Cancer | Anuradha Budhu, USA  12:05-12:30 | Discussion for Talks 25-29 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ 12:30-13:30 | Lunch Break 12:30-13:30 | Hepatitis Panel Business Meeting  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ *Moderators: Tatsuhiro Shubata & Xin Wei Wang * 13:30-13:40 | Young Investigator 7 | Immune Resilience to Cancer by Repurposing Mycobacterium Tuberculosis-specific CD4 Memory Th1 Cells | Burcu Temizoz 13:40-13:50 | Young Investigator 8 | Single Nanoparticle Mapping and Sorting in Biological Fluids and Breath Samples | Shuntaro Shimizu 13:50-14:00 | Young Investigator 9 | A Novel Mechanism of Driving Intrahepatic Cholangiocarcinoma | Takahiro Kodama, Japan 14:00-14:10 | Young Investigator 10 | Differential T-cell and Monocyte Responses in Hepatocellular Carcinoma Treated with Regorafenib Plus Nivolumab | Hyung-Don Kum, Korea 14:10-14:20 | Young Investigator 11 | Laminin y2 Monomer, a Novel Biomarker for Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection | Kouki Nio, Japan 14:20-14:30- Young Investigator 12 | Role of Hepcidin Upregulation and Proteolytic Cleavage of Ferroportin 1 in Hepatitis C Virus-induced Iron Accumulation | Kazuyoshi Ohta, Japan 14:30-15:00 | Discussion for Young Investigators 7-12 15:00-15:15 | Wrap-up and Plans for a Report | Ray Chung & Tatsuya Kanto 15:15 | Adjourn 37th Hepatitis / Immunology / Cancer Panel Meeting  --- ##            If you have any questions or technical issues please contact Annie King, [aking@crdfglobal.org](mailto:aking@crdfglobal.org)            ![](https://www.crdfglobal.org/wp-content/uploads/2021/12/crdf-logo-white.svg) #### Advancing U.S. national security by mitigating threats and enhancing opportunities through technology, innovation, and collaboration. ### Let us know how we can help you reach your goals [Facebook Facebook](https://www.facebook.com/CRDFGlobal) [Twitter](https://twitter.com/CRDFGlobal) [Instagram Instagram](https://www.instagram.com/crdfglobal/) [Linkedin Linkedin](https://www.linkedin.com/company/crdf-global)[Contact Us](https://insights.crdfglobal.org/contact-us?hsLang=en) - WHO WE ARE - [Our Story](https://crdfglobal.org/our-story/) - [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/) - [Leadership](https://insights.crdfglobal.org/leadership?hsLang=en) - [Our Experts](https://insights.crdfglobal.org/experts?hsLang=en) - [Partners](https://insights.crdfglobal.org/partners?hsLang=en) - WHAT WE DO - [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/) - [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/) - [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/) - [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/) - [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/) - [Health Security & Research](https://www.crdfglobal.org/what-we-do/global-health/) - HOW WE DELIVER - [Travel & Logistics](https://www.crdfglobal.org/capabilities/travel-logistics/) - [Security Strengthening](https://www.crdfglobal.org/capabilities/security-strengthening/) - [Fellowships & Exchanges](https://www.crdfglobal.org/capabilities/fellowships-and-exchanges/) - [Grants & Research Competitions](https://www.crdfglobal.org/capabilities/grants-research-competitions/) - [Technical & Professional Training](https://www.crdfglobal.org/capabilities/technical-and-professional-trainings/) - [Specialized Equipment Procurement](https://www.crdfglobal.org/capabilities/specialized-equipment-procurement/) - [Program Design and Management](https://www.crdfglobal.org/integrated-solutions/program-design-and-management/) - [Monitoring, Evaluation and Learning](https://www.crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/) - [Remote Training & Learning](https://www.crdfglobal.org/integrated-solutions/remote-training-and-learning/) - [Quality Framework](https://www.crdfglobal.org/integrated-solutions/quality-framework/) - COLLABORATE - [Become a Partner](https://www.crdfglobal.org/become-a-partner/) - [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/) - [Procurement & RFPs](https://insights.crdfglobal.org/rfp?hsLang=en) - [Funding & Grants](https://insights.crdfglobal.org/funding-opportunities?hsLang=en) - [WHERE WE WORK](https://crdfglobal.org/where-we-work/) - [NEWS & INSIGHTS](https://www.crdfglobal.org/news/) - [CAREERS](https://www.crdfglobal.org/careers/) [Privacy Policy](https://www.crdfglobal.org/data-privacy-policy/)    [Code of Conduct](https://www.crdfglobal.org/participant-code-of-conduct/) © 2026 CRDF Global - All rights reserved